Lanean...
What is the future of PEGylated therapies?
The tremendous potential of biologic drugs is hampered by short half-lives in vivo, resulting in significantly lower potency than activity seen in vitro. These short-acting therapeutic agents require frequent dosing profiles that can reduce applicability to the clinic, particularly for chronic condi...
Gorde:
| Argitaratua izan da: | Expert Opin Emerg Drugs |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4908577/ https://ncbi.nlm.nih.gov/pubmed/26583759 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14728214.2015.1113254 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|